這不是你的意志力問題。這是大腦的獎勵迴路在製造麻煩。最新發表於《eClinicalMedicine》的統合分析，分析了 25 項臨床試驗、超過 8,000 名受試者，告訴我們 GLP-1 藥物能做到什麼——以及做不到什麼。 It's not a willpower problem. It's your brain's reward circuitry causing trouble. The latest meta-analysis in eClinicalMedicine — 25 RCTs, over 8,000 participants — tells us what GLP-1 medications can and cannot do about it.
你有沒有這樣的經驗：才剛吃完飯，走過廚房，卻又鬼使神差地打開了冰箱——不是因為餓，而是因為…不知道為什麼，就是想打開來看看。然後一口接一口，等回過神來，已經吃了遠超過自己預期的量，心裡又充滿了懊悔。
這不是你特別沒有自制力。這是你的大腦，在悄悄地搞鬼。
Have you ever done this: you just finished dinner, you walk past the kitchen, and somehow you open the fridge — not because you're hungry, but because… something just pulls you there. One bite turns into many. You come back to yourself having eaten far more than you intended, followed by that familiar wave of regret.
This is not a failure of willpower. This is your brain, quietly causing trouble.
我們先把話說清楚：暴食傾向（binge eating）不等於「很喜歡吃東西」，也不是「偶爾吃太多」。它的核心特徵是失控感——在一段時間內吃了遠超預期的量，而且清楚感覺到自己無法停下來，即使已經飽了，身體說停，但腦子還在繼續。
Let's be clear about this upfront: binge eating is not the same as "really loving food" or "occasionally overeating." Its core characteristic is a sense of loss of control — eating far more than intended over a period of time, with a clear feeling that you cannot stop, even when full. The body says stop; the brain keeps going.
暴食症（Binge Eating Disorder, BED）是全球最常見的飲食疾患之一，影響超過 1,700 萬人，且約有三分之二的暴食症患者同時有過重或肥胖的問題。它與代謝症候群、糖尿病、心血管疾病，甚至情緒障礙都有密切關聯——偏偏在臨床上長期被低估與忽視。
Binge Eating Disorder (BED) is one of the most common eating disorders worldwide, affecting over 17 million people, with approximately two-thirds of those affected also having overweight or obesity. It is closely linked to metabolic syndrome, diabetes, cardiovascular disease, and mood disorders — yet has long been underrecognised and undertreated in clinical practice.
不一定要一次吃下一整個蛋糕才叫暴食。更常見的形式是：控制飲食的計畫一再被打破、對特定食物有壓倒性的渴望、吃東西時「關機」般失去意識、事後強烈的羞愧感與自責，以及用進食來應對壓力或負面情緒。如果這些聽起來很熟悉，你並不孤單。
Binge eating doesn't require eating an entire cake in one sitting. More common presentations include: repeatedly broken dietary plans, overwhelming cravings for specific foods, a "zoning out" quality during eating episodes, intense shame and self-blame afterwards, and using food to cope with stress or negative emotions. If this sounds familiar, you are not alone.
這裡要說一個讓很多人鬆了口氣的事：有暴食傾向的人，大腦的運作方式本來就和一般人不同。這不是藉口，而是神經科學的事實。
Here's something that tends to be a relief to hear: people with binge eating tendencies have brains that actually work differently. This is not an excuse — it is a neuroscientific fact.
大腦的獎勵迴路（尤其是多巴胺系統）在暴食症患者中，對食物的反應往往更強烈，同時控制衝動的能力相對較弱。這造成的結果就像是：腦子裡有個廣播員，不停地播送「吃！吃！吃！」，而你負責踩煞車的系統，偏偏不太靈光。
The brain's reward circuitry — especially the dopamine system — tends to respond more intensely to food in people with binge eating, while impulse control is comparatively weaker. The result is like having an announcer in your head broadcasting "Eat! Eat! Eat!" nonstop, while the system responsible for pressing the brakes is running a bit unreliably.
這就是為什麼 GLP-1 藥物引起了研究者的高度興趣。GLP-1 受體不只存在於腸道和胰臟——它們也存在於大腦，特別是與食慾調節、衝動控制和獎勵感知相關的區域。GLP-1 藥物越過血腦屏障後，可能直接調節這些讓人「停不下來」的神經迴路。
This is precisely why GLP-1 medications have attracted intense research interest. GLP-1 receptors are not only found in the gut and pancreas — they also exist in the brain, particularly in regions associated with appetite regulation, impulse control, and reward processing. After crossing the blood-brain barrier, GLP-1 medications may directly modulate the neural circuits that make stopping so difficult.
2026 年，倫敦大學學院（UCL）等機構的研究團隊在《eClinicalMedicine》發表了迄今最完整的統合分析，納入 25 項隨機對照試驗、8,069 名受試者，系統性評估各種 GLP-1 藥物（包括 liraglutide、semaglutide、tirzepatide 等）對暴食相關行為的影響。
In 2026, a research team from UCL and collaborating institutions published in eClinicalMedicine the most comprehensive meta-analysis to date — 25 RCTs, 8,069 participants — systematically evaluating the effects of various GLP-1 medications (including liraglutide, semaglutide, tirzepatide, and others) on binge eating-related behaviours.
結果如下：
Here is what they found:
在針對確診暴食症患者或專門以改善暴食為目標的試驗中，效果明顯更大（g = −0.60 vs 一般肥胖族群的 −0.27）。這提示 GLP-1 藥物對有暴食困擾的人，可能特別有幫助。
In trials specifically targeting patients with diagnosed binge eating disorder or aimed at reducing binge eating, effects were markedly larger (g = −0.60 vs. −0.27 in general obesity trials). This suggests GLP-1 medications may be particularly beneficial for those with binge eating difficulties.
數字之外，這篇研究還有一個難得的設計：他們邀請了 11 位有暴食傾向的真實患者，分享自己使用 GLP-1 藥物的親身經歷。這些來自「有生活實際體驗的人」的聲音，往往比任何統計數字都更直接。
Beyond the numbers, this study had an unusual feature: 11 real patients with binge eating tendencies were invited to share their lived experiences with GLP-1 medications. These voices from people with actual lived experience are often more immediate than any statistic.
「它讓什麼東西關掉了——食物不再是腦子最前端的東西了。」
"[It] switches something off — the food stops being at the forefront of your mind."
這句話說出了很多人的心聲。對有暴食傾向的人來說，最折磨人的往往不是「吃的行為本身」，而是那個不停在腦子裡插隊的食物念頭。GLP-1 藥物似乎能把那個廣播員的音量調小——不是靠意志力壓制，而是從神經層面讓它不再那麼響亮。
This quote resonates with many people. For those with binge eating tendencies, the most exhausting part is often not the eating behaviour itself, but the food thoughts that constantly cut to the front of the mind. GLP-1 medications seem to turn down the volume on that broadcaster — not through willpower, but by quieting it at the neurological level.
說了這麼多好消息，現在得說幾件必須知道的事——不是要潑冷水，而是因為這些事同樣重要。
Having shared the encouraging findings, there are a few essential things you need to know — not to dampen expectations, but because these matter equally.
「它只是一個工具——不是解決方案。短期有幫助，但心理支持也必須在場。」
"It's just a tool — it's not a fix. It will help for the short term, but the psychological support needs to be there too."
現有研究幾乎都是短期觀察。停止使用 GLP-1 藥物後，體重通常會反彈，暴食症狀也可能跟著捲土重來。藥物調低的音量，在沒有其他支持的情況下，可能只是暫時的。
Existing studies are almost all short-term. After stopping GLP-1 medications, weight typically rebounds, and binge eating symptoms may return. The volume the medication turned down may only be temporary without additional support in place.
暴食症的成因是多層面的——壓力、情緒調節、自我認同、飲食史都牽涉其中。藥物可以降低大腦對食物的衝動反應，但重建與食物的健康關係、學習新的情緒調節方式，仍需要心理治療的協助。
The causes of binge eating are multifaceted — stress, emotional regulation, self-image, and eating history are all involved. Medication can reduce the brain's impulsive food responses, but rebuilding a healthy relationship with food and learning new emotional regulation strategies still requires psychological therapy.
這篇統合分析中，只有 3 項試驗專門針對確診暴食症患者，且多數研究由藥廠資助，研究期間也較短。作者誠實指出：目前的證據仍屬「初步」，需要更多長期、獨立資助的研究。
Only 3 of the 25 trials specifically recruited patients with diagnosed BED, most studies were funded by pharmaceutical companies, and follow-up durations were relatively short. The authors honestly note that current evidence is still "preliminary" and requires more long-term, independently funded research.
研究參與者說得很好：「讓我們走到這裡的有很多事，要走出去也需要很多事的配合。」體重與飲食問題往往是複雜的生命故事的一部分。跨科別的整合照護——醫師、心理師、營養師的協同合作——才是最完整的解方。
As one participant put it: "Multiple things got us here, and multiple things will be required to get us out." Weight and eating difficulties are often part of complex life stories. Integrated multidisciplinary care — physicians, psychologists, and dietitians working together — is the most complete approach.
GLP-1 藥物能做到的：降低暴食衝動的頻率與強度、減少情緒性進食、讓你對飲食選擇有更多的意識與掌控感——從大腦的層面把那個廣播員的音量調小。
What GLP-1 medications can do: reduce the frequency and intensity of binge eating urges, decrease emotional eating, give you greater conscious awareness and control over food choices — turning down the volume on that broadcaster at the brain level.
GLP-1 藥物做不到的：解決暴食背後的心理根源、在停藥後維持效果、獨立替代心理治療。它是一個有力的輔助工具，不是終點。
What GLP-1 medications cannot do: resolve the psychological roots of binge eating, maintain effects after discontinuation, or independently replace psychological therapy. It is a powerful adjunct tool — not the destination.
根據 2026 年發表於《eClinicalMedicine》的統合分析，GLP-1 藥物能帶來中等程度的暴食嚴重程度降低，並顯著改善失控進食感與抑制力下降後的過食行為。然而，多數研究為短期、且由藥廠資助，作者也坦承目前證據屬於「初步」，需要更多長期、獨立資助的研究來確認。結果方向是一致且正面的，但不宜過度解讀為「萬靈丹」。
According to a 2026 meta-analysis published in eClinicalMedicine, GLP-1 medications produce moderate reductions in binge eating severity and significantly improve loss of control eating and disinhibited eating. However, most studies were short-term and industry-funded, and the authors honestly acknowledge that current evidence is "preliminary," requiring more long-term, independently funded research for confirmation. The direction of results is consistent and positive — but should not be interpreted as a cure-all.
不是。暴食傾向有明確的神經生物學基礎：大腦的獎勵迴路對食物反應更強烈，同時衝動控制的功能相對較弱。這就像是「油門踩很深、煞車卻沒那麼靈」。GLP-1 受體存在於大腦中，藥物能透過調節這些神經迴路來降低衝動，這正說明了暴食有其生理根源，並非個人道德或意志力的問題。
No. Binge eating has clear neurobiological underpinnings: the brain's reward circuitry responds more intensely to food while impulse control functions more weakly — like a car with a heavy accelerator and unreliable brakes. GLP-1 receptors exist in the brain, and medication can reduce impulses by modulating these neural circuits. This confirms that binge eating has physiological roots and is not a matter of personal morality or willpower.
研究顯示 GLP-1 藥物能降低情緒性進食分數約 30%（Hedges' g = −0.30，4 項研究），且各研究間的異質性低，說明效果方向非常一致。但情緒性進食通常與壓力、焦慮、孤獨等心理因素密切相關，光靠藥物往往不夠。GLP-1 藥物可以幫你降低進食衝動，但面對情緒的能力，需要透過心理治療來建立。
Research shows GLP-1 medications reduce emotional eating scores by approximately 30% (Hedges' g = −0.30, 4 studies), with low heterogeneity across studies — meaning the direction of effect is very consistent. However, emotional eating is often closely tied to psychological factors like stress, anxiety, and loneliness, and medication alone is usually insufficient. GLP-1 medications can reduce your eating impulses, but building the capacity to face emotions differently requires psychological therapy.
研究資料顯示，在針對確診暴食症患者的試驗中，GLP-1 藥物的效果更大（g = −0.60），相比一般肥胖族群（g = −0.27）明顯更顯著。換句話說，如果你有確診暴食症並同時有肥胖問題，GLP-1 藥物可能是一個特別值得考慮的輔助治療選項。不過這類試驗數量仍少，且建議同時配合心理治療。
Available data suggest that in trials specifically targeting patients with diagnosed BED, GLP-1 medications showed larger effects (g = −0.60), markedly greater than in general obesity trials (g = −0.27). In other words, if you have diagnosed BED alongside obesity, GLP-1 medications may be a particularly worthwhile adjunctive treatment option to consider. However, such trials are still limited in number, and concurrent psychological therapy is strongly recommended.
這是很重要的問題，也是目前研究的最大缺口之一。現有試驗大多屬於短期觀察，停藥後的長期追蹤資料非常有限。根據其他減重藥物的經驗，停藥後體重通常回升，食慾也會隨之增加——暴食症狀可能跟著反彈。這正是為什麼研究者和患者都強調：GLP-1 藥物必須搭配心理治療與行為介入，才能建立停藥後仍能持續的改變。
This is an important question and one of the biggest gaps in current research. Most existing trials offer only short-term data, and long-term follow-up after discontinuation is very limited. Based on experience with other weight-loss medications, weight typically rebounds after stopping, and appetite increases accordingly — binge eating symptoms may relapse as well. This is precisely why researchers and patients alike emphasise that GLP-1 medications must be combined with psychological therapy and behavioural intervention to build changes that persist after stopping the medication.
如果你長期受暴食衝動或情緒性進食困擾，高雄長庚體重管理中心的跨科別團隊——包含外科醫師、身心科、營養師——可以提供整合性的評估與支持，幫助你找到真正適合自己的方案，而不只是一顆藥。
If you have long struggled with binge eating urges or emotional eating, the multidisciplinary team at CGMH Weight Management Center — including surgeons, psychiatry support, and dietitians — can provide integrated assessment and support to help you find an approach truly tailored to your needs, not just a medication.
預約諮詢 → Book a Consultation →